Axinn at the ABA Antitrust Section Spring Meeting 2025
The week proved to be a success, as several Axinn attorneys were recognized with honors at the GCR Awards and the Antitrust Writing Awards. These recognitions reflect our continued commitment to excellence in antitrust law and thought leadership in the field. Our attorneys also moderated and participated in a range of panels, offering valuable insights on key industry topics. Read more below as Axinn associates share their key takeaways and reflections from the conference.
Viewpoints from the Week
Viewpoints from the Week
Axinn Associates at the Antitrust Spring Meeting: Antitrust Under Trump: Redo of the First Term, or Something New?
Axinn Associates at the Antitrust Spring Meeting: AG Antitrust Enforcement: “State” of Play
Axinn Associates at the Antitrust Spring Meeting: Considerations on Data Privacy and AI Usage for Healthcare Companies
Axinn Associates at the Antitrust Spring Meeting: Bridging Moats: Targeting Monopoly Entrenchment
Axinn Associates at the Antitrust Spring Meeting: Examining Algorithmic Pricing Tools
Axinn Associates at the Antitrust Spring Meeting: Merger Trials: Winning Strategies
Axinn Associates at the Antitrust Spring Meeting: Pharma Under the Antitrust Microscope
Axinn Associates at the Antitrust Spring Meeting: Has Competition in the U.S. Been Declining?
Axinn Associates at the Antitrust Spring Meeting: The Future of Healthcare Mergers
Axinn Associates at the Antitrust Spring Meeting: Enforcers’ Roundtable
A Winning Team!
Thought-Provoking Panels
As agency investigations and new merger guidelines continue to focus antitrust on the pharmaceutical ecosystem, panelists discussed legal and economic aspects of newer, less explored antitrust theories such as alleged harm from reduced innovation, bundled rebates, inappropriate patent listings, and self-preferencing PBM practices.
The FTC, DOJ, European Commission, and CMA have focused on monopolists’ exclusionary tactics such as “moat-building” and entrenchment. Panelists discussed recent enforcement actions to understand the trends in U.S., EU, and UK approach to monopoly entrenchment and moat-building.
Many believe that the U.S. economy has suffered from widespread decline in competitiveness, measured by increasing concentration or markups. Panelists discussed what the empirical evidence shows, and what the implications are for antitrust policy.
What Sets Us Apart
- Our 70+ full-time antitrust lawyers represent the world’s biggest corporations, including many of the Fortune 500
- Our track record of obtaining global clearance of combinations of significant rivals has built Axinn’s reputation as a “go-to” firm for strategic mergers and acquisitions
- We are lead defense counsel to some of the world’s largest companies in high-stakes treble damages, class action, and multi-district litigations, as well as federal and state investigations
- Our lawyers have defended companies and individuals in the largest price-fixing investigations of the last decade, and include former federal prosecutors and Antitrust Division leaders overseeing the Division’s criminal investigations, trials, and policy
- We combine our extensive experience before antitrust agencies around the world with our strategic agility and the ability to develop and present sophisticated econometric arguments
- Our team includes a broad range of experience in government, in-house, and private practice, ensuring a comprehensive, multifaceted, and bespoke approach to our clients’ needs
Antitrust Law in Action: Transactions, Litigation, and Cartels
High-Stakes Experience
Select Honors
Explore Our Other Practices
Focusing on antitrust, intellectual property, and high-stakes litigation, our extensive teams in the U.S. possess deep knowledge and client-side experience across a range of sectors, including technology, healthcare, life sciences, and consumer products.
